Holen Sie sich die Stockscreener-App
8.983
4.94%
0.423
Handel nachbörslich:
8.78
-0.203
-2.26%
Schlusskurs vom Vortag:
$8.56
Offen:
$8.52
24-Stunden-Volumen:
34,719
Relative Volume:
0.97
Marktkapitalisierung:
$28.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-68.80M
KGV:
-7.6778
EPS:
-1.17
Netto-Cashflow:
$-59.06M
1W Leistung:
+5.43%
1M Leistung:
+25.76%
6M Leistung:
+2,328%
1J Leistung:
+1,347%
1-Tages-Spanne:
$8.125
$9.12
1-Wochen-Bereich:
$7.13
$9.12
52-Wochen-Spanne:
$0.257
$9.90
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Vergleichen Sie PASG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
8.983 | 27.21M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
| 2021-07-01 | Eingeleitet | Raymond James | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
| 2021-02-04 | Eingeleitet | Guggenheim | Buy |
| 2021-01-25 | Eingeleitet | Wedbush | Outperform |
| 2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-03-24 | Eingeleitet | Cowen | Outperform |
| 2020-03-24 | Eingeleitet | Goldman | Buy |
| 2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
Lucid Capital Markets initiates Passage Bio stock with Buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Passage Bio stock with Buy rating - Investing.com India
Will Salona Cotspin Limited Benefit From Broader Market BounceLow Risk Investment Ideas & Maximize Gains Professionally - earlytimes.in
Passage Bio (PASG) Price Target Decreased by 45.15% to 33.15 - MSN
How Passage Bio Inc. stock compares to market leadersInsider Selling & AI Powered Market Trend Analysis - newser.com
Is Passage Bio Inc. stock bottoming out2025 Volatility Report & Proven Capital Preservation Tips - newser.com
Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates - MSN
How Passage Bio Inc. stock reacts to Fed rate cuts2025 Momentum Check & Low Risk High Win Rate Picks - newser.com
Applying chart zones and confluence areas to Passage Bio Inc.2025 Bull vs Bear & Safe Swing Trade Setups - newser.com
What momentum shifts mean for Passage Bio Inc.July 2025 Technicals & Safe Entry Trade Reports - newser.com
Chardan Capital Expects Reduced Earnings for Passage Bio - Defense World
Passage Bio Inc. stock trendline breakdownWeekly Trade Recap & Weekly Return Optimization Alerts - newser.com
Ranking Passage Bio Inc. among high performing stocks via toolsQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Passage Bio, Inc.Common Stock (NQ: PASG - FinancialContent
Using economic indicators to assess Passage Bio Inc. potentialQuarterly Earnings Report & Technical Confirmation Trade Alerts - newser.com
How Passage Bio Inc. stock reacts to global recession fearsEarnings Miss & Real-Time Volume Triggers - newser.com
Passage Bio Inc Stock Analysis and ForecastREITs Market Trends & Low Cost Wealth Plans - earlytimes.in
Chardan Capital Raises Passage Bio (NASDAQ:PASG) Price Target to $21.00 - Defense World
Passage Bio (NASDAQ:PASG) Price Target Raised to $21.00 - Defense World
Is Passage Bio Inc. stock a contrarian buyJuly 2025 Final Week & Weekly Stock Breakout Alerts - Fundação Cultural do Pará
What is Wedbush’s Forecast for Passage Bio FY2025 Earnings? - Defense World
Will Passage Bio Inc. price bounce be sustainableJuly 2025 Summary & Low Risk High Reward Ideas - newser.com
Why Passage Bio Inc. stock could rally in 2025Weekly Trend Recap & Stock Portfolio Risk Control - newser.com
Why Passage Bio Inc. stock remains a top recommendationEarnings Growth Report & Low Drawdown Investment Ideas - newser.com
Chardan Capital Raises Price Target on Passage Bio (PASG) to $21 - GuruFocus
Chardan Raises Price Target on Passage Bio to $21 From $6, Keeps Buy Rating - MarketScreener
3 Best Biotech Stocks to Buy Now, 11/12/2025, According to Top Analysts - TipRanks
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF) and Passage Bio (PASG) - The Globe and Mail
Passage Bio Cuts Losses And Gains Analysts’ Confidence - Finimize
PASSAGE BIO, INC. Q3 Loss Decreases, Beats Estimates - Nasdaq
Passage Bio (PASG) Advances PBFT02 Clinical Trials and FDA Discu - GuruFocus
[10-Q] Passage BIO, Inc. Quarterly Earnings Report | PASG SEC FilingForm 10-Q - Stock Titan
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Passage Bio Q3 net loss narrows to $7.7 mln - MarketScreener
Passage Bio, Inc. Announces Active Enrollment in upliFT-D Study and Regulatory Alignment with FDA - Quiver Quantitative
PASG: Clinical trial progress, reduced net loss, and strong cash position support future milestones - TradingView
[8-K] Passage BIO, Inc. Reports Material Event | PASG SEC FilingForm 8-K - Stock Titan
Passage Bio (NASDAQ: PASG) narrows net loss to $7.7M, y/y from $19.3M as costs decline - Stock Titan
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Passage Bio Inc-Aktie (PASG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Sep 15 '25 |
Buy |
6.99 |
11,900 |
83,175 |
623,704 |
| Lynx1 Capital Management LP | 10% Owner |
Sep 11 '25 |
Buy |
6.96 |
325 |
2,261 |
592,021 |
| Lynx1 Capital Management LP | 10% Owner |
Jul 24 '25 |
Buy |
5.71 |
66,423 |
379,455 |
591,696 |
| Lynx1 Capital Management LP | 10% Owner |
Jul 23 '25 |
Buy |
5.74 |
49,302 |
283,033 |
525,273 |
| Lynx1 Capital Management LP | 10% Owner |
Jul 22 '25 |
Buy |
5.44 |
13,123 |
71,338 |
475,971 |
0.53%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):